Northwest Biotherapeutics, Inc. (NWBO)
| Market Cap | 691.20M |
| Revenue (ttm) | 1.37M |
| Net Income (ttm) | -474.11M |
| Shares Out | 927.78M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,681,035 |
| Open | 0.750 |
| Previous Close | 0.745 |
| Day's Range | 0.000 - 0.000 |
| 52-Week Range | 0.730 - 2.150 |
| Beta | 0.71 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NWBO
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The compa...
News
Northwest Biotherapeutics Announces $15 Million Financing
BETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today an...
Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility
BETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today an...
3 Biotechs to Avoid Like the Plague in July
Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.
7 Penny Stocks to Watch With Crypto News Sparking a Market Dip
Looking for 7 penny stocks that could be buy the dip candidates? Check these out The post 7 Penny Stocks to Watch With Crypto News Sparking a Market Dip appeared first on Penny Stocks to Buy, Picks, New...
UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)
BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today ann...
Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility
BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today a...
Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?
In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.